Woodcock cleared of conflict of interest

FDA's Office of Chief Counsel and the HHS Inspector General concluded there was no conflict of interest involved in CDER Director Janet Woodcock's review of two generic versions of marketed anticoagulant Lovenox enoxaparin. She had voluntarily recused herself in August after one of the generic manufacturers, Amphastar Pharmaceuticals Inc. (Rancho Cucamonga, Calif.), filed a complaint citing four papers co-authored by Woodcock and scientists from Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), the maker of the other generic (See BioCentury, Feb. 23, 2009). ...